Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2930MR)

This product GTTS-WQ2930MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2930MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4444MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ14577MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ12221MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ15009MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ1871MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ8985MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ1672MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ289MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW